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Cancer is a complex and heterogeneous disease thought to be caused by multiple genetic lesions. 33 
The recent finding that enzymes of the tricarboxylic acid (TCA) cycle are mutated in cancer 34 
rekindled the hypothesis that altered metabolism might also have a role in cellular 35 
transformation. Attempts to link mitochondrial dysfunction to cancer uncovered the unexpected 36 
role of small molecule metabolites, now known as oncometabolites, in tumorigenesis. In this 37 
review, we describe how oncometabolites can contribute to tumorigenesis. We propose that 38 
lesions of oncogenes and tumour suppressors are only one of the possible routes to 39 
tumorigenesis, which include accumulation of oncometabolites triggered by environmental cues.  40 
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Background 43 
Cancer is a complex and multifactorial disease. Although its malignant features have been known for 44 
centuries, it was not until the advent of modern biology that the molecular determinants of cancer 45 
transformation have been elucidated. In 1911, pioneering work from Peyton Rous showed that avian 46 
sarcomas were transmissible to other healthy fowls through a filtrate of the tumours devoid of cells 47 
[1, 2]. Later on, the agent present in those extracts and responsible for tumour formation was 48 
identified as a retrovirus, later called Rous Sarcoma Virus (RSV). This important discovery started the 49 
field of tumour virology and led to the identification of the first oncogene v-Src [3-6], first in 50 
retroviruses and then in normal avian DNA [7]. The emerging idea was that cancer was caused by 51 
alterations of the genome. Since then, other oncogenes, including MYC, RAS, ERBB, PI3K [2, 6] and 52 
the first tumour suppressor gene RB1 [8, 9] were discovered. The causative role of RB1 inactivation 53 
in retinoblastoma formation reinforced the concept of cancer initiation driven by genomic 54 
alterations. These discoveries led Knudson and colleagues to hypothesise a “multiple-hit” model of 55 
tumorigenesis, where multiple genetic alterations are required to achieve full blown transformation 56 
[8]. We now know that tumorigenesis requires the acquisition of multiple enabling features, the 57 
hallmarks of cancer, among which metabolic rewiring is becoming increasingly recognised [10, 11]. 58 
In a seminal paper, Shim et al. showed that Lactate Dehydrogenase A is a target of the proto-59 
oncogene Myc and is required for c-Myc-induced anchorage-independent growth in both human 60 
and mouse cellular models [12]. Since then, scientists have uncovered several aspects of the 61 
metabolic reprogramming of cancer, and realised that not only dysregulated metabolism is required 62 
to sustain proliferation but it also affects tumour microenvironment and the immune response [11]. 63 
The discovery that mutations in the metabolic genes Fumarate Hydratase (FH) [13], Succinate 64 
Dehydrogenase (SDH) [14-17], and Isocitrate dehydrogenase (IDH) [18-21] lead to cancer further 65 
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supported a primary role of metabolic alterations in tumorigenesis. Thanks to these discoveries, a 66 
novel paradigm is emerging whereby mitochondrial metabolites that accumulate in these conditions 67 
act as oncogenic signalling molecules, becoming bona fide oncometabolites. Recent data suggest 68 
that reprogramming of cellular metabolism occurs both as direct and indirect consequence of 69 
oncogenic mutations and that environmental cues, such as hypoxia, could also affect the abundance 70 
of oncometabolites, amplifying oncogenic cascades. In this review we describe the main oncogenic 71 
functions of oncometabolites and how their abundance can be affected by genetic mutations and 72 
environmental cues. 73 
TCA cycle enzymes mutations and the emerging paradigm of oncometabolite-74 
driven tumorigenesis  75 
SDH was the first mitochondrial enzyme found mutated in cancer [14]. It was the first time that 76 
mutations of a mitochondrial enzyme, once thought to be incompatible with life [22], were linked to 77 
tumour predisposition. This and the subsequent discovery of FH mutations in renal cancer catalysed 78 
a substantial effort to elucidate the molecular links between mitochondrial dysfunction and 79 
tumorigenesis. These major findings are reported below. 80 
Succinate Dehydrogenase (SDH) 81 
SDH is an enzyme of the TCA cycle involved in the conversion of succinate to fumarate and a key 82 
component of the mitochondrial respiratory chain. This enzyme is composed of four subunits, SDHA, 83 
SDHB, SDHC, SDHD; and two assembly factors, SDHF1 and SDHF2 [23, 24]. Mutations in SDH are 84 
found in familial paragangliomas and pheochromocytomas [14-17], renal carcinomas [25], T-Cell 85 
leukaemia [26], and gastrointestinal stromal tumours [27]. SDH deficiency causes profound 86 
metabolic changes. Recent work from Gottlieb and co-workers showed that mouse Sdhb-/- cells have 87 
a high demand of extracellular pyruvate and utilise glucose-derived carbons for aspartate 88 
biosynthesis through pyruvate carboxylation [28].  89 
One of the most striking features of SDH-deficient cells is the accumulation of succinate [29], 90 
a metabolite implicated in tumorigenesis and, for this reasons, recently defined an oncometabolite 91 
[30]. Among its many functions, succinate is a competitive inhibitor of α-ketoglutarate (aKG)-92 
dependent dioxygenases (aKGDD), a class of enzymes involved in a plethora of biological processes. 93 
For instance, succinate inhibits prolyl-hydroxylases (PHDs), aKGDDs involved in the degradation of 94 
Hypoxia Inducible Factor (HIF), leading to the aberrant stabilisation of HIFs even when oxygen is 95 
abundant, a condition called pseudohypoxia [31]. Succinate inhibits other aKGDDs, including Ten-96 
Eleven Translocation proteins (TETs), enzymes involved in DNA demethylation, [32], leading to CpG 97 
island hypermethylation [33]. Succinate also causes the inhibition of Histone Lysine Demethylases 98 
(KDMs), aKGDDs involved in histone demethylation [32], causing even further epigenetic changes 99 
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[33, 34]. Interestingly, DNA hypermethylation phenotype was associated with dedifferentiation and 100 
increased invasion potential of SDH-deficient tumours [33, 35]. However, the molecular mechanisms 101 
behind this phenotypic switch are still under investigation.  102 
Fumarate Hydratase 103 
FH is an enzyme of the TCA cycle that converts fumarate to malate. Whilst homozygous FH 104 
mutations cause fumaric aciduria, a condition associated with infantile encephalopathy and brain 105 
malformations [36], heterozygous FH mutations followed by the loss of heterozygosity of the second 106 
allele cause Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) [13, 37]. FH is also mutated in 107 
paragangliomas, pheochromocytomas [38, 39], downregulated in sporadic clear cell carcinomas [40] 108 
and deleted in neuroblastoma [41]. Cristal structure of human FH showed that clinically-relevant 109 
mutations affect evolutionary conserved regions involved in either the catalytic activity or the 110 
folding and stability of the protein [42], leading to abnormal accumulation of fumarate [43-45]. The 111 
loss of FH also leads to a complex rewiring of cell metabolism. For instance, FH loss leads to an 112 
increased uptake of glutamine that is diverted into haem synthesis and bilirubin excretion to 113 
maintain mitochondrial NADH production and mitochondrial potential. Also, the accumulation of 114 
fumarate in FH-deficient cells leads to the reversal of the urea cycle enzyme argininosuccinate lyase, 115 
causing the production of argininosuccinate [44, 45]. More importantly, the reverse activity of 116 
argininosuccinate lyase makes FH-deficient cells auxotrophic for arginine and sensitive to its 117 
depletion[45]. In normal condition, argininosuccinate is produced from aspartate and citrulline by 118 
argininosuccinate synthase (ASS1). It is possible to speculate that in FH-deficient cells ASS1 activity is 119 
somehow inhibited by arginosuccinate accumulation and therefore aspartate diverted into other 120 
pathways such as pyrimidine biosynthesis, favouring tumour growth [46]. 121 
Fumarate has been implicated in tumorigenesis of HLRCC and, for this reason, included in 122 
the list of “oncometabolites” [47]. Similarly to succinate, fumarate inhibits several aKGDDs, including 123 
PHDs, leading to pseudohypoxia [48]. Of note, the non-canonical activation of NF-kB signalling by 124 
fumarate also contributes to the pseudohypoxic phenotype in FH-deficient cells [49]. Although 125 
pseudohypoxia has been considered an important driver of tumorigenesis, recent data showed that 126 
HIFs are dispensable for the formation of benign pre-tumorigenic lesions in Fh1-deficent mice [50]. 127 
Recent findings identified the Since Abelson murine leukaemia viral oncogene homolog-1 (ABL-1) as 128 
another potential driver in fumarate-dependent tumorigenesis [51]. Interestingly, ABL-1 inhibitors 129 
suppress the invasion capabilities of FH-deficient cells both in vitro and in vivo. Mechanistically, 130 
through ABL-1 activation, fumarate stimulates an antioxidant response mediated by transcription 131 
factor NFE2-related factor 2 (NRF2) and a metabolic rewiring through activation of mammalian 132 






fumarate-dependent tumorigenesis, which include broad epigenetic changes [52], caused by 134 
inhibition of histone and DNA demethylases [32] and post translation modification caused by 135 
fumarate. Indeed, fumarate is a mild electrophilic molecule and can react with thiol residues of 136 
proteins through a process called succination [53-56]. This post-translational modification is a 137 
distinctive feature of FH-deficient tumours and now used for diagnostic purposes [54]. Although 138 
several succinated proteins have been identified in FH-deficient cells [56, 57], the biological roles of 139 
this process are still under investigation. It was recently reported that succination of mitochondrial 140 
Aconitase (ACO2) impairs its enzymatic activity [57] and succination of Kelch-Like ECH-associated 141 
protein-1 (KEAP-1) inhibits its negative modulatory effect on the transcription factor NFE2-related 142 
factor 2 (NRF2) [50, 58]. NRF2 activation has been previously reported as pro-tumorigenic event 143 
[59], but is role in FH-deficient tumours is still debated. The thiol residue of the antioxidant 144 
tripeptide Glutathione (GSH) is also subject of succination [60, 61] and its depletion causes oxidative 145 
stress, which induces senescence in primary FH-deficient kidney cells. Of note, genetic ablation of 146 
p21, a major player in senescence induction, in FH-deficient mice induces transformation of benign 147 
cysts confirming the tumour-suppressive role of senescence in FH-mediated tumorigenesis [61]. 148 
However, the role of fumarate in ROS regulation is still under investigation. For instance, a recent 149 
work by Jin and collaborators showed that fumarate is required for activation of the antioxidant 150 
protein Glutathione peroxidase (GPx) by direct binding [62].  151 
Isocitrate Dehydrogenase (IDH1/IDH2) 152 
Isocitrate dehydrogenases (IDHs) are homodimeric enzymes responsible for the oxidative 153 
decarboxylation of isocitrate to aKG. Three different isoforms of IDH have been described, which 154 
have distinct subcellular compartmentalisation. IDH3 is a NAD+-dependent mitochondrial enzyme, 155 
core component of the TCA cycle. The other two IDH isoforms (IDH1 and IDH2) are NADP+-156 
dependent proteins expressed respectively in cytosol and mitochondria [24, 63]. Heterozygous 157 
missense mutations affecting IDH1 and IDH2 were found in gliomas [18, 19] and in acute myeloid 158 
leukaemia (AML) [20, 21]. At odds with SDH and FH, IDH mutations are gain-of-function mutations 159 
and confer to the enzyme the ability to produce the oncometabolite R-2-hydroxyglutarate (R-2HG) 160 
[64, 65]. 2HG, the reduced form of akG, is naturally present in two optic isomers, R-2HG and L-2HG. 161 
In normal cells, 2HG is a minor by-product of metabolism and its levels are kept low by the activity of 162 
a conserved family of proteins, the L/D-2-hydroxyglutarate dehydrogenases (L2HGDH and R2HGDH) 163 
[66, 67], which convert 2HG to aKG. Homozygous germline mutations in these two enzymes are 164 
responsible for a severe form of 2HG aciduria characterised by developmental abnormalities and 165 
premature death in children [67, 68]. Moreover, mutations in L2HGDH have been associated with 166 
brain tumours [69] and recently with kidney cancer [70]. Both isomers of 2HG can affect the 167 
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enzymatic activity of aKGDD. Whilst the role of R-2HG in PHD inhibition and HIF1A stabilisation is still 168 
controversial [71, 72], this metabolite was shown to inhibit both TETs and KDMs [72, 73]. 169 
Consistently, IDH1-mutant tumours exhibit DNA hypermethylation in gliomas [74] and leukemia [75], 170 
and histone hypermethylation [76]. Evidence that TET2 and IDH1/2 mutations are mutually exclusive 171 
in AML tumours [75] supports the notion that TETs inhibition and the ensuing DNA 172 
hypermethylation are instrumental to IDH-driven tumorigenesis. This hypothesis has been recently 173 
corroborated by the finding that DNA hypermethylation causes reduced CCCTC-binding factor (CTCF) 174 
binding to DNA, leading to aberrant activation of the oncogene Platelet-derived growth factor 175 
receptor (PDGFRA) [77] in gliomas. Other mechanisms have been proposed to contribute to IDH-176 
dependent tumorigenesis. For istance, 2HG accumulation inhibits ATP Synthase within the 177 
mitochondria activating a series of downstream signals that involve mTOR suppression [78]. 178 
Moreover, 2HG accumulation is also driven by proto-oncogene MYC activation in aggressive breast 179 
cancer. Interestingly, those breast tumours are characterised by the same distinctive DNA 180 
hypermethylation typical of IDH mutant tumours [79]. More importantly, the incubation of cells with 181 
R-2HG promotes cytokine independence and alters differentiation in hematopoietic cells, 182 




Succinate, fumarate, and 2HG: overlapping and distinct functions. 187 
The brief description above suggests that signalling cascades elicited by fumarate, succinate, and 188 
2HG, share some common targets but also exhibit distinct features, which can explain the different 189 
types of tumours associated with their accumulation (Fig. 1). The converging signatures, mostly 190 
mediated by aKGDD inhibition, include pseudohypoxia and broad epigenetic changes, such a DNA 191 
and histones hypermethylation. Interestingly, recent studies showed that pseudohypoxic genes, 192 
besides being regulated by HIFs, are also transcriptionally controlled by TETs. Therefore, epigenetic 193 
changes are required for a full pseudohypoxic response triggered by these metabolites. However, 194 
these metabolites have different IC50 for TETs and KDMs [81], suggesting that their epigenetic effect 195 
might have different outcomes, with fumarate being the most effective TETs inhibitor and 2HG the 196 
poorest. These metabolites exert other distinct biological functions. As indicated above, fumarate 197 
accumulation leads to protein succination, triggering a plethora of biological changes that may 198 
synergise with or counteract aKGDDs inhibition.[51]. Finally, accumulation of 2HG has been shown  199 
to increase protein succinylation via inhibition of SDH and subsequent accumulation of succinyl-CoA 200 




induces resistance to apoptosis. Interestingly, these are not the only different downstream signals 202 
activated by fumarate and 2HG accumulation. Indeed, fumarate and 2HG elicit opposite effects on 203 
mTOR signalling that could be relevant for the development of specific tumour types [51, 78]. 204 
Therefore, although characterised by a very similar chemical structure, succinate, fumarate, and 205 
2HG, appear to have distinct biological roles, well beyond inhibition of aKGDDs.  206 
Environmental cues regulates oncometabolite production 207 
The observation that 2HG is sufficient to promote tumorigenesis [80] raised the possibility that 208 
environmental cues that increase this metabolite could contribute to tumorigenesis, without 209 
underpinning IDH mutations. In support to this hypothesis, it has been shown that hypoxia leads to 210 
the production of 2HG  (Fig.2), either via reductive carboxylation [83] or via promiscuous substrate 211 
usage of lactic dehydrogenase A (LDHA) [84] and malic dehydrogenase 1/2 (MDH1/2) [85]. Since 212 
hypoxia is a common feature of solid tumours [86] it is possible that hypoxia-driven production of 213 
2HG elicits (epi)genetic changes that drive or amplify the process of tumorigenesis.     214 
 2-HG is not the only oncometabolite whose levels are altered by hypoxia. During ischemia, 215 
succinate significantly accumulates and its oxidation is responsible for ROS generation during 216 
reperfusion [87]. Other cues trigger oncometabolite accumulation. For instance, fumarate was 217 
shown to accumulate in hyperglycemic conditions [55, 88] (Fig.2), likely as a consequence of 218 
mitochondrial dysfunction caused by glucose accumulation [89, 90]. We hypothesise that fumarate 219 
accumulation observed in diabetes [88, 90], could, at least in part, explain the increase cancer risk in 220 
these patients. Together, these studies seem to suggest that environmental or nutritional cues may 221 
cause dysregulation of mitochondrial function, leading to oncometabolite accumulation in the 222 
absence of underpinning oncogenic mutations.  223 
Future perspectives 224 
Oncometabolites are emerging as key components of the communication between mitochondria 225 
and the nucleus. Chronic accumulation of these small molecules triggered by genetic or 226 
environmental cues may alter the epigenetic landscape of the cell eliciting oncogenic signalling 227 
cascades. This new paradigm of tumorigenesis challenges the role of gene mutations as the exclusive 228 
driving mechanism of tumorigenesis and suggests that the latter may be only one of the possible 229 
mechanisms that leads to transformation.  230 
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 579 
Figure legends 580 
Fig.1 Schematic representation of overlapping features of tumours harbouring FH, SDH, and IDH 581 
mutations. 582 
Mutations in FH, SDH, and IDH lead to the accumulation of fumarate, succinate, and 2HG, 583 
respectively, activating a plethora of signalling cascades. Converging signatures, mainly mediated by 584 
aKGDD inhibition, include pseudohypoxia, histone and DNA hypermethylation. The colour of text 585 
indicates metabolic alterations (red), epigenetic alterations (blue), post-translational modifications 586 





Fig.2 An oncometabolic perspective of tumorigenesis 590 
Schematic representation of how oncometabolite affect the process of tumorigenesis. The indicated 591 
oncometabolites can accumulate as a consequence of mutations of TCA cycle enzymes or 592 
environmental cues, such as hypoxia or hyperglycemia. These metabolites can act as proper 593 
oncogenic triggers and can drive transformation even in the absence of genetic alterations. 594 
 595 
 596 
